Decoding microRNA drivers in atherosclerosis.

Area of Science:

• Genomics
• Molecular Biology
• Cardiovascular Research

Background:

• The human genome contains a vast amount of non-protein-coding sequences, including diverse non-coding RNAs (ncRNAs).
• Micro-RNAs (miRNAs), a class of short ncRNAs, are emerging as critical regulators in cellular processes and disease pathogenesis.
• Atherosclerosis, a chronic inflammatory disease driven by lipid accumulation and vascular injury, involves complex regulatory mechanisms.
• Despite conventional therapies, a significant residual risk of cardiovascular disease persists, highlighting the need for novel therapeutic approaches.

Purpose of the Study:

• To review the current understanding of non-coding RNAs (ncRNAs), with a specific focus on micro-RNAs (miRNAs), in the context of atherosclerosis.
• To explore the novel biological mechanisms through which miRNAs contribute to the development and progression of atherosclerotic cardiovascular disease.
• To identify and discuss potential therapeutic avenues targeting miRNAs for the management of atherosclerosis and residual cardiovascular risk.

Main Methods:

• Literature review of existing research on ncRNA and miRNA in cardiovascular disease.
• Analysis of current therapeutic strategies for atherosclerosis and their limitations.
• Identification of emerging research on miRNA-mediated pathways in atherosclerosis.

Main Results:

• miRNAs play significant roles as master regulators in the pathogenesis of atherosclerotic cardiovascular disease.
• Dysregulation of specific miRNAs is implicated in key processes of atherosclerosis, including inflammation, lipid accumulation, and vascular remodeling.
• miRNAs show potential as biomarkers for disease progression and treatment response.
• miRNA mimics and repressors represent a promising new class of drugs to complement existing therapies.

Conclusions:

• Non-coding RNAs, particularly miRNAs, are integral to the development and progression of atherosclerosis.
• Targeting miRNAs offers a novel therapeutic strategy to address residual cardiovascular risk and improve patient outcomes.
• Further research into miRNA biology and therapeutic applications is warranted for effective atherosclerosis management.